Results 271 to 280 of about 3,286,390 (370)

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, Maria J Barrero, Diego Megías, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez‐Dominguez, Sara Monzón, Isabel Cuesta, Laura Sánchez, Rodrigo Barderas, Jesús García‐Donas, Alberto Martín, Ignacio Pérez de Castro   +17 more
wiley   +1 more source

CAR-NK cell therapy: promise and challenges in solid tumors. [PDF]

Front Immunol
Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L.   +4 more
europepmc   +1 more source

Persistent presence of common ALL-antigen (cALLa)-positive cells in regenerating bone marrow after cessation of maintenance therapy in ALL of childhood [PDF]

, 1985
J. A. J. M. Bakkeren, Gam de Vaan
openalex   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia [PDF]

, 1982
W Hiddemann, BD Clarkson, T Buchner, MR Melamed, Michael Andreeff   +4 more
openalex   +1 more source

Future of cell therapy

Annals of Physical and Rehabilitation Medicine, 2014
openaire   +2 more sources

Clinical significance of stratifying prostate cancer patients through specific circulating genes

Molecular Oncology, Volume 19, Issue 5, Page 1310-1331, May 2025.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian, Edouard Jarry, Arynne Santos, Quentin Vesval, Lucie Hamel, Rafael Sanchez‐Salas, Alexis Rompré‐Brodeur, Wassim Kassouf, Raghu Rajan, Fadi Brimo, Marie Duclos, Armen Aprikian, Simone Chevalier   +12 more
wiley   +1 more source

Immunomodulatory agents and cell therapy for patients with type 1 diabetes. [PDF]

Arch Endocrinol Metab
Rodacki M, Silva KR, Araujo DB, Dantas JR, Ramos MEN, Zajdenverg L, Baptista LS.   +6 more
europepmc   +1 more source

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Molecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O. Estevam, Jean‐Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S. Fraser, Martin Figeac, Alexis B. Cortot, Etienne Rouleau, David Tulasne   +14 more
wiley   +1 more source

Cost-effective strategies for CAR-T cell therapy manufacturing. [PDF]

Mol Ther Oncol
Abdo L, Batista-Silva LR, Bonamino MH.
europepmc   +1 more source